AlphAIalphai — Financial news for AI agents
insidermonkey.comSEP 42 min read$RVMD

Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough?

Revolution Medicines (RVMD) received FDA approval for Rasonque, a RAS inhibitor for metastatic pancreatic cancer. The 30-day supply is priced at $39,800. Clinical trials showed improved survival rates compared to chemotherapy. The company faces challenges in payer negotiations and broader adoption.

Original reporting
insidermonkey.com
Published Sep 4, 2026, 5:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 6:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough? — source image
Source · insidermonkey.com
Decision brief

The 30-second read

$RVMDBullishHigh
01

Why it matters

The approval provides a new revenue stream but hinges on payer coverage given the $39,800 price tag.

02

Market read

First disclosure of FDA approval and pricing creates a fresh catalyst for RVMD, likely driving short‑term trading interest.

03

What to watch

Potential safety concerns and need for broader payer support could delay revenue.

Relevance 9/10Novelty 9/10Timing: today

Background

Revolution Medicines (NASDAQ:RVMD) received FDA approval for its oral RAS inhibitor Rasonque for metastatic pancreatic cancer.

Company-level read

Ticker impact

$RVMDBullishHigh confidence
Context

FDA approval of Rasonque with a $39,800 WAC price and strong Phase 3 survival data.

Expected impact

upward pressure on RVMD as launch begins, volatility expected on coverage news.

Evidence & confidence

First report of approval and pricing; market has not priced the launch yet.

Market effects

Sector

Boosts biotech RAS inhibitor space and may lift peers developing similar agents.

Regional

U.S. oncology market sees new high‑price oral therapy, could affect payer negotiations.

Global

Limited to U.S. biotech investors; modest global ripple.

Counterpoint

What could challenge this read

High price may limit uptake and pressure margins, leading to muted stock reaction.

Key entities

  • company
    Revolution Medicines, Inc.

    Biotech firm developing RAS pathway inhibitors.

  • regulator
    FDA

    U.S. Food and Drug Administration granting approval.

Read at source← All news

Related articles

SEP 4
$RVMDHighAI 8/10

Michael Osterholm Says He's Staying Four More Years as Public Health's Systems Buckle — BigGo Finance

Revolution Medicines' FDA-approved cancer drug, divarasib and razabi, targets RAS protein, previously deemed undruggable. CEO Mark Goldsmith bet the company on this target, leading to a successful Phase 3 trial. Michael Osterholm, 73, delayed retirement to address public health challenges, launching the Vaccine Integrity Project. David Baker, Nobel laureate, focuses on designing novel proteins and mentoring scientists.

finance.biggo.com2 min
SEP 3
$RVMDHighAI 9/10

Daraxonrasib shrinks tumours in one-third of lung cancer patients

Revolution Medicines Inc. (RVMD) reported that its experimental drug daraxonrasib shrank tumors in 33% of advanced lung cancer patients in a Phase 1/2 trial, with symptom improvements. The study, published in the New England Journal of Medicine, involved 136 patients with RAS gene mutations. The drug targets multiple RAS mutations and showed a median response duration of 11.5 months. Side effects were common, with rash, diarrhea, and nausea affecting many patients. The company is now conducting

mugglehead.com2 min
SEP 3
$RVMDMedAI 8/10

RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer

Revolution Medicines (RVMD) presented updated Phase 1/2 trial data for Rasonque in non-small cell lung cancer (NSCLC), showing a 42% overall response rate, 8.3-month median progression-free survival, and 16-month median overall survival. Truist Securities noted the results support RVMD's Phase 3 lung cancer study. Rasonque was recently FDA-approved for pancreatic cancer, with Phase 3 results expected in December 2027 for NSCLC.

biospace.com2 min
SEP 3
$RVMDMedAI 8/10

NEJM publishes daraxonrasib NSCLC data supporting Phase III program

Revolution Medicines (RVMD) published Phase I/II data in NEJM showing daraxonrasib's antitumor activity in RAS-mutant NSCLC. The study reported a 42% response rate and 8.3-month median progression-free survival. The company is advancing the drug in a Phase III trial. Daraxonrasib was recently approved for pancreatic cancer, marking the company's first commercial product.

allsci.com2 min
SEP 2
$RVMDMedAI 9/10

RVMD Shares React as Phase 1/2 RASONQUE Data Published in NEJM

Revolution Medicines (RVMD) announced the publication of Phase 1/2 trial results for RASONQUE in the New England Journal of Medicine. The data showed promising efficacy and safety in treating advanced RAS mutant NSCLC. The company has a market cap of $44.85 billion and is currently unprofitable, with a high Price-to-Sales ratio of 70.5x. Insider activity shows significant selling, while guru ownership trends are mixed.

gurufocus.com3 min
SEP 2
$RVMDHighAI 9/10

Revolution Medicines Announces NEJM Publication of Phase 1/2 RASONQUE Data Supporting Ongoing Phase 3 RASolve 301 Trial in RAS Mutant NSCLC

Revolution Medicines (RVMD) announced NEJM publication of Phase 1/2 trial data for RASONQUE (daraxonrasib) in RAS mutant NSCLC. The trial showed 42% objective response rate and 89% disease control rate in a subgroup, with manageable safety profile. The data support the ongoing Phase 3 RASolve 301 trial, following recent FDA approval for pancreatic cancer.

quiverquant.com3 min